Literature DB >> 2176111

Estimation of epidermal growth factor receptor in 177 breast cancers: correlation with prognostic factors.

M Bolla1, M Chedin, C Souvignet, J Marron, C Arnould, E Chambaz.   

Abstract

Steroid receptors (ER, PR) and EGF-receptor were determined on 177 loco-regional primary breast cancers. Binding assay for EGF receptor was performed using a single saturating concentration of 125I-EGF incubated with membranes in the presence or absence of unlabeled EGF. With threshold values of 5 fmol/mg and 10 fmol/mg for EGF-R and steroid receptors respectively, we noted an inverse relationship between the expression of EGF-R, and ER and PR. EGF-R expression is decreased with tumor differentiation.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2176111     DOI： 10.1007/BF01809293

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  20 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  [Prognostic value of estrogen and progesterone receptors in the operable breast cancer: results of a uni- and multifactorial analysis].

Authors:  B Chevallier; F Heintzman; B Asselain; J P Dauce; P Bastit; Y Graic; P Brunelle; J P Basuyau; M Comoz
Journal:  Bull Cancer       Date:  1988       Impact factor: 1.276

Review 3.  Flow cytometry, cellular DNA content, and prognosis in human malignancy.

Authors:  D E Merkel; L G Dressler; W L McGuire
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

4.  Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: the role of adjuvant chemotherapy.

Authors:  J M Raemaekers; L V Beex; G F Pieters; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

5.  Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels.

Authors:  S L Fitzpatrick; J Brightwell; J L Wittliff; G H Barrows; G S Schultz
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

6.  Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture.

Authors:  S L Fitzpatrick; M P LaChance; G S Schultz
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

7.  Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors.

Authors:  J C Delarue; S Friedman; H Mouriesse; F May-Levin; H Sancho-Garnier; G Contesso
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

8.  Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma.

Authors:  M A Ríos; A Macías; R Pérez; A Lage; L Skoog
Journal:  Anticancer Res       Date:  1988 Jan-Feb       Impact factor: 2.480

9.  [EGF receptors in human breast cancer. Relation to hormonal receptors].

Authors:  J P Peyrat; J Bonneterre; B Vandewalle; J Djiane; J Lefebvre
Journal:  Ann Endocrinol (Paris)       Date:  1984       Impact factor: 2.478

10.  The influence of hormone receptors and hormonal adjuvant therapy on disease-free survival in breast cancer: a multifactorial analysis.

Authors:  L Caldarola; P Volterrani; B Caldarola; M Lai; A Jayme; P Gaglia
Journal:  Eur J Cancer Clin Oncol       Date:  1986-02
View more
  10 in total

1.  Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Authors:  Mary E Irwin; Kelly L Mueller; Natacha Bohin; Yubin Ge; Julie L Boerner
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

Review 2.  The epidermal growth factor receptor in breast cancer.

Authors:  S B Fox; A L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

3.  Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters.

Authors:  M Bolla; M Chedin; M Colonna; J Marron-Charrière; B Rostaing-Puissant; D Pasquier; M H Panh; P Winckel; E M Chambaz
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Protein tyrosine kinase activity as a prognostic parameter in breast cancer, a pilot study.

Authors:  M Bolla; B R Rostaing-Puissant; M Chedin; C Souvignet; J Marron-Charriere; M Colonna; E Berland; E M Chambaz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Epidermal growth factor receptor in breast cancer: storage conditions affecting measurement, and relationship to steroid receptors.

Authors:  W R McLeay; D J Horsfall; R Seshadri; D A Morrison; G T Saccone
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 6.  EGF receptor in neoplasia and metastasis.

Authors:  K Khazaie; V Schirrmacher; R B Lichtner
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

Review 7.  Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer.

Authors:  J S Biscardi; R C Ishizawar; C M Silva; S J Parsons
Journal:  Breast Cancer Res       Date:  2000-03-07       Impact factor: 6.466

8.  The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer.

Authors:  Jennifer M Wymant; Stephen Hiscox; Andrew D Westwell; Sylvie Urbé; Michael J Clague; Arwyn T Jones
Journal:  J Cancer       Date:  2016-12-09       Impact factor: 4.207

9.  The rapamycin-regulated gene expression signature determines prognosis for breast cancer.

Authors:  Argun Akcakanat; Li Zhang; Spiridon Tsavachidis; Funda Meric-Bernstam
Journal:  Mol Cancer       Date:  2009-09-24       Impact factor: 27.401

10.  Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.

Authors:  Giorgio Secreto; Elisabetta Venturelli; Elisabetta Meneghini; Maria Luisa Carcangiu; Biagio Paolini; Roberto Agresti; Cristina Pellitteri; Franco Berrino; Massimo Gion; Patrizia Cogliati; Giuseppina Saragò; Andrea Micheli
Journal:  BMC Cancer       Date:  2012-12-14       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.